Vista Pharmaceuticals Ltd Stock Price Today (NSE: VISTAPH)
Fundamental Score
Vista Pharmaceuticals Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Vista Pharmaceuticals Ltd share price today is ₹6.00, up +7.33% on NSE/BSE as of 22 September 2026. Vista Pharmaceuticals Ltd (VISTAPH) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹36.93 (Cr). The 52-week high for VISTAPH share price is ₹10.50 and the 52-week low is ₹5.32. The company has a Return on Equity (ROE) of -29.46% and a debt-to-equity ratio of 0.27.
Vista Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance
Vista Pharmaceuticals Ltd share price chart: -15.54% return over the past month. 52-week high ₹10.50, 52-week low ₹5.32.
Vista Pharmaceuticals Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹5.99 | ₹5.99 | ₹5.35 | ₹5.59 | 2.33K (Cr) | |
| ₹5.99 | ₹5.99 | ₹5.62 | ₹5.88 | 15.32K (Cr) | |
| ₹5.69 | ₹5.95 | ₹5.48 | ₹5.61 | 20.30K (Cr) | |
| ₹5.41 | ₹5.70 | ₹5.32 | ₹5.36 | 32.62K (Cr) | |
| ₹5.77 | ₹5.90 | ₹5.70 | ₹5.77 | 6.37K (Cr) | |
| ₹5.60 | ₹5.80 | ₹5.50 | ₹5.75 | 6.56K (Cr) | |
| ₹5.89 | ₹6.10 | ₹5.55 | ₹5.60 | 26.68K (Cr) | |
| ₹5.85 | ₹6.07 | ₹5.54 | ₹5.87 | 3.60K (Cr) | |
| ₹6.00 | ₹6.17 | ₹5.50 | ₹5.80 | 33.78K (Cr) | |
| ₹6.48 | ₹6.48 | ₹5.83 | ₹5.95 | 4.75K (Cr) |
Vista Pharmaceuticals Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹6.46 | ₹6.48 | ₹5.32 | ₹5.59 | -13.47% | |
| ₹6.50 | ₹7.28 | ₹5.81 | ₹6.02 | -7.38% | |
| ₹7.13 | ₹7.77 | ₹6.10 | ₹6.63 | -7.01% | |
| ₹8.60 | ₹8.60 | ₹6.57 | ₹7.16 | -16.74% | |
| ₹7.80 | ₹8.60 | ₹6.83 | ₹8.59 | +10.13% | |
| ₹6.11 | ₹8.55 | ₹6.05 | ₹7.74 | +26.68% | |
| ₹6.90 | ₹8.87 | ₹5.71 | ₹6.11 | -11.45% | |
| ₹8.29 | ₹8.50 | ₹6.60 | ₹6.90 | -16.77% | |
| ₹8.20 | ₹8.84 | ₹7.00 | ₹7.20 | -12.20% | |
| ₹8.94 | ₹9.90 | ₹7.90 | ₹8.14 | -8.95% | |
| ₹9.90 | ₹10.10 | ₹7.63 | ₹8.86 | -10.51% | |
| ₹10.07 | ₹10.50 | ₹9.17 | ₹9.82 | -2.48% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Vista Pharmaceuticals Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Vista Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of VISTAPH across key market metrics for learning purposes.
Positive Indicators
4 factors identified
Robust Profit Growth (23.28%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Consistent Growth Track Record (33.57% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Conservative Debt Levels (D/E: 0.27)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
10 factors identified
Below-Average Return on Equity (-29.46%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-34.85%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (-103.07%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Revenue Contraction (-100.00%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Weak Interest Coverage (-13.67x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Liquidity Concerns (Current Ratio: 0.92)
Observation: Current assets may not adequately cover short-term liabilities.
Analysis: Current ratio <1.0 raises working capital concerns.
Negative Free Cash Flow (₹-22.28 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Low Promoter Commitment (21.19%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
Limited Institutional Interest (FII+DII: 0.02%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Vista Pharmaceuticals Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Vista Pharmaceuticals Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Vista Pharmaceuticals LtdVista Pharmaceu...Selected✓ VISTAPH • 524711 | 8/100 | ₹6.00₹6 | ₹36.93₹36.93 | — — | -29.46%Poor -29.46% Poor | -34.85%Poor -34.85% Poor | 0.27Excellent 0.3 Excellent | — — | 33.57%Excellent 33.57% Excellent | 0.00% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1864.90₹1865 | ₹447445.46₹447445.46 | 37.00Average 37.0 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9488.00₹9488 | ₹251432.00₹251432.00 | 86.09Average 86.1 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4930.00₹4930 | ₹166860.78₹166860.78 | 78.75Average 78.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1127.40₹1127 | ₹112514.52₹112514.52 | 25.13Average 25.1 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1363.10₹1363 | ₹110118.03₹110118.03 | 32.66Average 32.7 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1937.00₹1937 | ₹104646.43₹104646.43 | 95.61Average 95.6 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1698.90₹1699 | ₹97754.71₹97754.71 | 26.55Average 26.5 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.00₹2100 | ₹96022.50₹96022.50 | 17.35Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1145.00₹1145 | ₹95607.50₹95607.50 | 29.59Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2265.00₹2265 | ₹93544.50₹93544.50 | 45.77Average 45.8 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price447445.46 Cr
- Divi's Laboratories Limited share price251432.00 Cr
- Torrent Pharmaceuticals Limited share price166860.78 Cr
- Zydus Lifesciences Limited share price112514.52 Cr
- Cipla Limited share price110118.03 Cr
Vista Pharmaceuticals Ltd Quarterly Performance
Latest quarterly metrics for VISTAPH — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-100.00%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
23.28%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
33.57%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Vista Pharmaceuticals Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for VISTAPH — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Vista Pharmaceuticals Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Vista Pharmaceuticals Ltd (VISTAPH) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Vista Pharmaceuticals Ltd
About VISTAPH (Vista Pharmaceuticals Ltd)
Vista Pharmaceuticals Ltd is a dynamic and globally-focused pharmaceutical company committed to developing, manufacturing, and distributing high-quality, affordable healthcare solu...tions. With a foundation built on decades of expertise, VISTAPH operates at the intersection of innovation and accessibility, striving to improve patient outcomes through a diverse portfolio of pharmaceutical products. The company's strength lies in its integrated approach, encompassing research and development, rigorous quality control, and a customer-centric distribution network that spans both domestic and international markets. VISTAPH's commitment to excellence is reflected in its state-of-the-art manufacturing facilities and adherence to stringent regulatory standards, ensuring the safety and efficacy of its products. VISTAPH's product range includes a wide array of prescription and over-the-counter generic medications, designed to address a broad spectrum of therapeutic needs. From cardiovascular health to pain management and infectious diseases, VISTAPH offers solutions in the form of tablets, capsules, and liquid formulations, catering to diverse patient preferences and requirements. The company's focus on generic drugs allows it to provide cost-effective alternatives to branded medications, making healthcare more accessible to a wider population. This commitment to affordability does not compromise on quality; each product undergoes thorough testing and quality assurance protocols to meet the highest industry standards. Headquartered in Hyderabad, India, VISTAPH leverages its strategic location and skilled workforce to serve a global clientele. The company is dedicated to fostering innovation and expanding its product pipeline to address unmet medical needs. VISTAPH continually invests in research and development activities, exploring new formulations and drug delivery systems to enhance therapeutic efficacy and patient compliance. Furthermore, the company is actively pursuing strategic partnerships and collaborations to expand its reach and market presence, solidifying its position as a trusted provider of pharmaceutical solutions worldwide.
Company Details
Key Leadership
VISTAPH Share Price: Frequently Asked Questions
What is the current share price of Vista Pharmaceuticals Ltd?
Vista Pharmaceuticals Ltd (VISTAPH) trades at ₹6.00 on NSE and BSE. Market cap ₹36.93 (Cr). Educational data only.
What is the P/E ratio of Vista Pharmaceuticals Ltd?
Vista Pharmaceuticals Ltd has a P/E of N/Ax vs industry average 34.89x.
What is the Bull Run score for Vista Pharmaceuticals Ltd?
Vista Pharmaceuticals Ltd has a Bull Run score of 8/100 based on 25+ financial parameters.
Does Vista Pharmaceuticals Ltd pay dividends?
Vista Pharmaceuticals Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Vista Pharmaceuticals Ltd?
Vista Pharmaceuticals Ltd has ROE of -29.46%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Vista Pharmaceuticals Ltd?
Vista Pharmaceuticals Ltd has debt-to-equity of 0.27.
Is Vista Pharmaceuticals Ltd a good investment?
Bull Run gives Vista Pharmaceuticals Ltd a score of 8/100. This is not investment advice — consult a SEBI-registered advisor.